Fair value measurements and investments (Tables)

3 Months Ended

Mar. 31, 2023

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Schedule of Financial Assets and Liabilities Recorded at Fair Value on Recurring Basis

The fair value measurements of the Company’s financial assets and liabilities measured on a recurring basis were as follows:

	March 31, 2023											December 31, 2022
(Unaudited, U.S. Dollars, in thousands)	Level 1		Level 2			Level 3			Total			Total
Assets
Neo Medical convertible loan agreements	$	—	$	—		$	7,180		$	7,180		$	7,140
Neo Medical preferred equity securities		—		6,084			—			6,084			6,084
Bone Biologics equity securities		—		—			—			—			—
Other investments		—		—			1,829			1,829			1,726
Total	$	—	$	6,084		$	9,009		$	15,093		$	14,950
Liabilities
Lattus contingent consideration	$	—	$	—			(11,500	)	$	(11,500	)	$	—
Spinal Kinetics contingent consideration		—		—			—			—			—
Deferred compensation plan		—		(1,415	)		—			(1,415	)		(1,515	)
Total	$	—	$	(1,415	)	$	(11,500	)	$	(12,915	)	$	(1,515	)

Schedule of Reconciliation of Investments in Equity Securities

The table below presents a reconciliation of the beginning and ending balances of the Company’s investment in Neo Medical preferred equity securities:

(Unaudited, U.S. Dollars, in thousands)	2023		2022
Fair value of Neo Medical preferred equity securities at January 1	$	6,084	$	5,413
Conversion of loan into preferred equity securities		—		671
Fair value of Neo Medical preferred equity securities at March 31		6,084		6,084
Cumulative unrealized gain on Neo Medical preferred equity securities		413		413

Schedule of Reconciliation For Contingent Consideration Measured At Fair Value Using Significant Unobservable Inputs

The following table provides a reconciliation of the beginning and ending balances for the Spinal Kinetics contingent consideration measured at estimated fair value using significant unobservable inputs (Level 3):

(Unaudited, U.S. Dollars, in thousands)	2023		2022
Spinal Kinetics contingent consideration estimated fair value at January 1	$	—	$	17,200
Decrease in fair value recognized in acquisition-related amortization and remeasurement		—		(5,500	)
Spinal Kinetics contingent consideration estimated fair value at March 31	$	—	$	11,700

Fair Value, Inputs, Level 3 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Schedule of Reconciliation For Convertible Loans Measured At Fair Value Using Significant Unobservable Inputs

The following table provides a reconciliation of the beginning and ending balances of the Convertible Loans, measured at fair value using significant unobservable inputs (Level 3):

(Unaudited, U.S. Dollars, in thousands)	2023			2022
Fair value of Neo Medical Convertible Loans at January 1	$	7,140		$	7,148
Interest recognized in interest income, net		116			112
Foreign currency remeasurement recognized in other expense, net		61			(69	)
Unrealized loss recognized in other comprehensive loss		(137	)		(740	)
Conversion of Second Convertible Loan into preferred equity securities		—			(671	)
Fair value of Neo Medical Convertible Loans at March 31		7,180			5,780
Amortized cost basis of Neo Medical Convertible Loans at March 31		6,084			5,581

Schedule of Changes in Valuation of Securities

The following table provides quantitative information related to certain key assumptions utilized within the valuation as of March 31, 2023:

(Unaudited, U.S. Dollars, in thousands)	Fair Value as of  March 31, 2023		Unobservable inputs	Estimate
Neo Medical Convertible Loan	$	7,180	Cost of equity discount rate		18.0	%
			Estimated equity volatility		77.5	%